Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
ATIR(TM) for Reduction of Transplant Related Mortality Following an Allogeneic Stem Cell Transplantation Using a Mismatched Donor
The study is currently open for enrollment in centers in Europe and Canadaand is designed to serve as a registration trial for European approval.
"We are very pleased to initiate the registration study following excellent clinical results from the phase I/II study with ATIR(TM)." says Dr.Manja Bouman, CEO of Kiadis Pharma. "ATIR(TM) has shown a low TRM at one year post transplantation and a high overall survival in a patient population with no standard treatment options left. As an orphan product addressing a high unmet need, we aim to take advantage of a fast development path for ATIR(TM)."
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.